Ohio State University Comprehensive Cancer Center

🇺🇸United States

Country: 🇺🇸United States

Ownership: Subsidiary

Employees: -

Market Cap: -

Website: http://www.cancer.osu.edu

Clinical Trials

Omega-3 Fatty Acids in Preventing Joint Symptoms in Patients With Stage I-III Breast Cancer Receiving Anastrozole, Exemestane, or Letrozole

Not Applicable

Completed

Conditions: Stage IIIB Breast Cancer
Stage IIIC Breast Cancer
Stage II Breast Cancer
Stage IA Breast Cancer
Recurrent Breast Cancer
Stage IB Breast Cancer
Stage IIIA Breast Cancer

Interventions: Other: Placebo
Dietary Supplement: omega-3 fatty acid supplement
Other: Clinical assessments
Other: Assessment of therapy complications
Procedure: Magnetic Resonance Imaging
Procedure: Correlative/special studies

First Posted Date: 2011-11-23

Last Posted Date: 2023-02-27

Lead Sponsor: Ohio State University Comprehensive Cancer Center

Target Recruit Count: 44

Registration Number: NCT01478477

Locations: 🇺🇸
Ohio State University Medical Center, Columbus, Ohio, United States

Transoral Robotic Surgery in Treating Patients with Benign or Malignant Tumors of the Head and Neck

Not Applicable

Recruiting

Conditions: Recurrent Adenoid Cystic Carcinoma of the Oral Cavity
Recurrent Verrucous Carcinoma of the Larynx
Recurrent Verrucous Carcinoma of the Oral Cavity
Stage 0 Lip and Oral Cavity Cancer
Stage I Squamous Cell Carcinoma of the Hypopharynx
Stage II Verrucous Carcinoma of the Larynx
Stage IVA Verrucous Carcinoma of the Larynx
Stage IVB Adenoid Cystic Carcinoma of the Oral Cavity
Stage IVB Verrucous Carcinoma of the Larynx
Stage IVC Squamous Cell Carcinoma of the Lip and Oral Cavity

Interventions: Procedure: transoral robotic surgery
Procedure: quality of life assessment

First Posted Date: 2011-11-17

Last Posted Date: 2024-11-15

Lead Sponsor: Ohio State University Comprehensive Cancer Center

Target Recruit Count: 600

Registration Number: NCT01473784

Locations: 🇺🇸
Ohio State University Medical Center, Columbus, Ohio, United States

Phase 1b Food Based Modulation of Biomarkers in Human Tissues at High-Risk for Oral Cancer.

Phase 1

Completed

Conditions: Stage 0 Paranasal Sinus and Nasal Cavity Cancer
Stage II Squamous Cell Carcinoma of the Hypopharynx
Stage III Squamous Cell Carcinoma of the Oropharynx
Stage IVB Squamous Cell Carcinoma of the Lip and Oral Cavity
Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma
Salivary Gland Squamous Cell Carcinoma
Stage 0 Laryngeal Cancer
Stage II Squamous Cell Carcinoma of the Nasopharynx
Stage II Verrucous Carcinoma of the Oral Cavity
Stage III Squamous Cell Carcinoma of the Nasopharynx

Interventions: Other: placebo
Other: questionnaire administration
Other: laboratory biomarker analysis
Drug: chemoprevention

First Posted Date: 2011-11-10

Last Posted Date: 2020-02-20

Lead Sponsor: Ohio State University Comprehensive Cancer Center

Target Recruit Count: 70

Registration Number: NCT01469429

Locations: 🇺🇸
Ohio State University Medical Center, Columbus, Ohio, United States

Study of Patients With Stage IV Malignant Melanoma Using PS-341 (Bortezomib, Velcade) and Interferon-alpha-2b in Malignant Melanoma

Phase 1

Completed

Conditions: Melanoma

Interventions: Drug: Bortezomib
Drug: Interferon Alfa-2b

First Posted Date: 2011-10-31

Last Posted Date: 2015-01-13

Lead Sponsor: Ohio State University Comprehensive Cancer Center

Target Recruit Count: 16

Registration Number: NCT01462773

Locations: 🇺🇸
Ohio State University, Columbus, Ohio, United States

A Phase II Trial of Panobinostat and Lenalidomide in Patients With Relapsed or Refractory Hodgkin's Lymphoma

Phase 2

Completed

Conditions: Adult Mixed Cellularity Hodgkin Lymphoma
Recurrent Adult Hodgkin Lymphoma
Adult Nodular Lymphocyte Predominant Hodgkin Lymphoma
Adult Nodular Sclerosis Hodgkin Lymphoma
Adult Lymphocyte Depletion Hodgkin Lymphoma
Adult Lymphocyte Predominant Hodgkin Lymphoma

Interventions: Drug: panobinostat
Drug: lenalidomide

First Posted Date: 2011-10-27

Last Posted Date: 2017-11-14

Lead Sponsor: Ohio State University Comprehensive Cancer Center

Target Recruit Count: 24

Registration Number: NCT01460940

Locations: 🇺🇸
The Ohio State University Medical Center, Columbus, Ohio, United States
🇺🇸
Washington University, Saint Louis, Missouri, United States

Ohio State University Multiple Myeloma and Amyloidosis Data Registry and Sample Resource

Recruiting

Conditions: AL Amyloidosis
Multiple Myeloma
Monoclonal Gammopathy of Undetermined Significance
Plasma Cell Dyscrasias

First Posted Date: 2011-08-03

Last Posted Date: 2023-10-12

Lead Sponsor: Ohio State University Comprehensive Cancer Center

Target Recruit Count: 5000

Registration Number: NCT01408225

Locations: 🇺🇸
Ohio State University Medical Center, Columbus, Ohio, United States

Community Awareness, Resources and Education (CARE II): Project 3

Completed

Conditions: Uterine Cervical Cancer

First Posted Date: 2011-02-18

Last Posted Date: 2018-04-25

Lead Sponsor: Ohio State University Comprehensive Cancer Center

Target Recruit Count: 191

Registration Number: NCT01299714

Dietary Fish and Omega 3 Fatty Acids for Breast Cancer Prevention

Phase 1

Completed

Conditions: Breast Cancer

Interventions: Dietary Supplement: Lovaza-Omega 3 fatty acid capsules
Other: Dietary fish (canned salmon, albacore)

First Posted Date: 2011-01-25

Last Posted Date: 2019-08-30

Lead Sponsor: Ohio State University Comprehensive Cancer Center

Target Recruit Count: 25

Registration Number: NCT01282580

Locations: 🇺🇸
The Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States

Study of Carfilzomib in Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL) or Prolymphocytic Leukemia (PLL)

Phase 1

Completed

Conditions: Recurrent Small Lymphocytic Lymphoma
B-cell Chronic Lymphocytic Leukemia
Hematopoietic/Lymphoid Cancer
Prolymphocytic Leukemia
Refractory Chronic Lymphocytic Leukemia

Interventions: Drug: carfilzomib
Other: Cytokine Assessment
Other: Pharmacodynamic Studies
Other: Proteosome Inhibition Assessment
Other: Pharmacogenomic Studies

First Posted Date: 2010-09-30

Last Posted Date: 2016-05-09

Lead Sponsor: Ohio State University Comprehensive Cancer Center

Target Recruit Count: 21

Registration Number: NCT01212380

Locations: 🇺🇸
Ohio State University Medical Center, Columbus, Ohio, United States

Feasibility Study of a 60 Minute Rapid Infusion Rituximab Protocol in Patients With B-cell Malignancies

Phase 2

Completed

Conditions: Indolent or Intermediate Grade B-cell Malignancy

Interventions: Drug: Rituximab

First Posted Date: 2010-09-22

Last Posted Date: 2017-12-20

Lead Sponsor: Ohio State University Comprehensive Cancer Center

Target Recruit Count: 52

Registration Number: NCT01206777

Locations: 🇺🇸
The Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy